Edward W Holt, MD
Gastroenterology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
- Since medical school
- 21 years
- Graduated 2005
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Alta Bates Summit Medical Center · Alta Bates Summit Medical Center - Alta Bates Camp · California Pacific Medical Center- Van Ness Campus · Sutter Delta Medical Center · Sutter Medical Center, Sacramento. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Holt’s office at (415) 600-0140 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- Sutter Delta Medical CenterAntioch, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.173, Oct 2024 – Sep 2025
- Sutter Medical Center, SacramentoSacramento, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.9 (12 to 15.9) · 992 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.066, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.335, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.215, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.46, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.253, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Sutter Delta Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 5 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.173 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.98 (0 to 2.03) · 561 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.47 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 176.46 (114.75 to 238.17) · 31 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 113 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.3 · 260 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.5 · 56 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 1,274 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.02 to 0.46) · 3,285 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 3,374 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.47 (1.02 to 5.93) · 364 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.16 (0.49 to 3.83) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.63 (0 to 18.4) · 26 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.71 (0.2 to 3.22) · 81 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.24 (0 to 1.07) · 2,713 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.962 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 116 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 316 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 20 · 83 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 7.1 · 298 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 27.3 · 269 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 283 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.7 to 17.1) · 529 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.3) · 45 cases | No different | Jan 2024 – Dec 2024 |
What patients said (610 patients answered, 13% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 70% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 60% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 64% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Sutter Medical Center, Sacramento
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (12 to 15.9) · 992 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.066 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.335 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.215 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.46 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.253 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.12 (0.29 to 1.94) · 2,408 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.78 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.68 (126.66 to 206.71) · 180 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 292 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 543 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 425 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 5,216 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.29) · 9,948 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.45) · 10,968 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.04 (1.53 to 4.56) · 3,983 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.33 (0.2 to 2.46) · 2,033 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.78 (1.69 to 3.87) · 3,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.79 (6.29 to 13.29) · 2,100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.62 (4.04 to 9.2) · 2,018 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.29 to 2.98) · 867 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.54 (0.07 to 1.01) · 8,613 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 294 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 598 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 924 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.5 · 488 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.3 · 638 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 600 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.9 to 6.1) · 992 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 298 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 249 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.7 to 14.6) · 1,326 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 934 cases | No different | Jan 2024 – Dec 2024 |
What patients said (700 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$77,444
Medicare paid this office $77,444 for 278 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $22,726 | $105 |
| Long return visit (40+ min) | 67 | $17,214 | $150 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $8,501 | $149 |
| Return visit (30+ min) | 56 | $6,581 | $98 |
| Long return visit (40+ min) | 40 | $6,543 | $123 |
See all 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $22,726 | $105 |
| Long return visit (40+ min) | 67 | $17,214 | $150 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $8,501 | $149 |
| Return visit (30+ min) | 56 | $6,581 | $98 |
| Long return visit (40+ min) | 40 | $6,543 | $123 |
| Return visit (30+ min) | 20 | $2,007 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,190 | $70 |
| Measurement of liver stiffness | 17 | $444 | $26 |
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | – | – | – | – | 11 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
278 Original Medicare patients in 2024. Average age 71 · Under 65 16% · 85 and older 4% · Women 46% · Also on Medicaid 35% · Health risk score 2.35. Sicker patients than 9 in 10 peers; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 49% · Chronic kidney disease 44% · Coronary heart disease 29% · Depression 25% · Heart failure 22% · Atrial fibrillation 20% · Cancer 15% · COPD 14% · Dementia 8% · Stroke 5%.
The office billed $329,029, Medicare allowed $101,662 and paid $77,444; for 674 services of 27 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 278 | 674 | 71 | 2.35 | $329,029 | $77,444 |
| 2023 | 311 | 691 | 70 | 2.41 | $328,424 | $78,746 |
| 2022 | 298 | 605 | 70 | 2.41 | $275,633 | $69,753 |
| 2021 | 322 | 748 | 68 | 2.37 | $329,852 | $83,396 |
| 2020 | 344 | 785 | 68 | 2.69 | $362,830 | $82,483 |
| 2019 | 345 | 827 | 68 | 2.67 | $387,981 | $83,798 |
| 2018 | 359 | 821 | 67 | 2.70 | $393,502 | $83,979 |
| 2017 | 325 | 697 | 67 | 2.70 | $327,817 | $66,150 |
| 2016 | 369 | 870 | 66 | 2.43 | $433,487 | $89,364 |
| 2015 | 334 | 735 | 65 | 2.52 | $361,139 | $77,559 |
| 2014 | 289 | 676 | 65 | 2.47 | $364,226 | $72,968 |
| 2013 | 119 | 321 | 64 | 2.67 | $152,668 | $33,929 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $21,156 | $108 |
| Long return visit (40+ min) | 73 | $18,221 | $149 |
| Return visit (30+ min) | 81 | $9,447 | $99 |
| Long return visit (40+ min) | 38 | $6,160 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $5,854 | $150 |
| Return visit (30+ min) | 26 | $2,319 | $80 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,507 | $72 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $898 | $82 |
| Measurement of liver stiffness | 25 | $559 | $22 |
2022: 10 services
| Long return visit (40+ min) | 74 | $17,835 | $151 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 50 | $13,230 | $89 |
| Return visit (30+ min) | 67 | $8,833 | $105 |
| Long return visit (40+ min) | 42 | $6,444 | $124 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $5,246 | $175 |
| New patient visit (45+ min) | 20 | $2,824 | $141 |
| New patient visit (45+ min) | 18 | $2,071 | $115 |
| Return visit (30+ min) | 16 | $1,585 | $83 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $1,299 | $87 |
| Measurement of liver stiffness | 20 | $453 | $23 |
2021: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 56 | $21,384 | $93 |
| Long return visit (40+ min) | 91 | $18,266 | $147 |
| Return visit (30+ min) | 67 | $7,921 | $100 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,765 | $181 |
| Long return visit (40+ min) | 42 | $7,392 | $123 |
| New patient visit (60+ min) | 16 | $2,820 | $176 |
| Telephone medical discussion with physician, 21-30 minutes | 27 | $2,800 | $100 |
| Return visit (30+ min) | 28 | $2,515 | $79 |
| New patient visit (45+ min) | 14 | $1,763 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,624 | $62 |
| Measurement of liver stiffness | 20 | $566 | $28 |
2020: 13 services
| Long return visit (40+ min) | 101 | $18,465 | $121 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $17,670 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $7,737 | $184 |
| Long return visit (40+ min) | 55 | $7,373 | $90 |
| Telephone medical discussion with physician, 21-30 minutes | 40 | $4,425 | $98 |
| Return visit (30+ min) | 38 | $4,153 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $4,108 | $66 |
| New patient visit (60+ min) | 19 | $3,363 | $177 |
| New patient visit (60+ min) | 13 | $2,025 | $156 |
| Return visit (30+ min) | 20 | $1,386 | $69 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $942 | $72 |
| Measurement of liver stiffness | 22 | $659 | $30 |
| Measurement of liver stiffness | 16 | $158 | $10 |
2019: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 81 | $26,127 | $93 |
| Long return visit (40+ min) | 101 | $17,351 | $118 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 58 | $11,852 | $182 |
| Long return visit (40+ min) | 55 | $7,145 | $92 |
| Return visit (30+ min) | 41 | $4,289 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $3,450 | $64 |
| New patient visit (60+ min) | 14 | $2,492 | $178 |
| New patient visit (60+ min) | 17 | $2,380 | $140 |
| Measurement of liver stiffness | 48 | $1,367 | $28 |
| Return visit (30+ min) | 17 | $1,327 | $66 |
| New patient visit (45+ min) | 12 | $1,225 | $102 |
2018: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 86 | $25,105 | $93 |
| Long return visit (40+ min) | 117 | $20,236 | $120 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 55 | $10,442 | $180 |
| Long return visit (40+ min) | 65 | $7,318 | $91 |
| Return visit (30+ min) | 30 | $2,930 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $2,911 | $65 |
| New patient visit (60+ min) | 14 | $2,086 | $149 |
| New patient visit (60+ min) | 11 | $1,862 | $169 |
| Return visit (30+ min) | 16 | $960 | $60 |
| Measurement of liver stiffness | 19 | $596 | $31 |
| Measurement of liver stiffness | 21 | $244 | $11 |
2017: 14 services
| Long return visit (40+ min) | 108 | $18,356 | $117 |
| Long return visit (40+ min) | 67 | $9,598 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $9,327 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,703 | $181 |
| Return visit (30+ min) | 46 | $4,262 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $3,489 | $65 |
| Return visit (30+ min) | 36 | $2,514 | $64 |
| New patient visit (60+ min) | 12 | $2,077 | $173 |
| New patient visit (45+ min) | 13 | $1,414 | $109 |
| New patient visit (45+ min) | 12 | $1,348 | $112 |
| Needle biopsy of liver through skin | 12 | $911 | $76 |
| Measurement of liver stiffness | 44 | $504 | $11 |
| Ultrasonic guidance for needle placement | 12 | $320 | $27 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 12 | $58 | $5 |
2016: 10 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 72 | $25,246 | $93 |
| Long return visit (40+ min) | 148 | $19,760 | $106 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 66 | $12,699 | $181 |
| Long return visit (40+ min) | 66 | $8,358 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $3,429 | $65 |
| New patient visit (60+ min) | 20 | $3,293 | $165 |
| Return visit (30+ min) | 28 | $2,807 | $91 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 21 | $2,385 | $114 |
| Return visit (30+ min) | 15 | $1,097 | $69 |
| Measurement of liver stiffness | 37 | $379 | $10 |
2015: 11 services
| Long return visit (40+ min) | 121 | $19,024 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 62 | $17,504 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $8,561 | $182 |
| Long return visit (40+ min) | 52 | $7,801 | $94 |
| Return visit (30+ min) | 39 | $3,448 | $84 |
| New patient visit (60+ min) | 21 | $3,302 | $157 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $3,060 | $65 |
| New patient visit (60+ min) | 16 | $2,299 | $144 |
| New patient visit (45+ min) | 13 | $1,506 | $116 |
| Return visit (30+ min) | 14 | $979 | $61 |
| Measurement of liver stiffness | 21 | $276 | $13 |
2014: 11 services
| Long return visit (40+ min) | 104 | $17,218 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $12,595 | $93 |
| Long return visit (40+ min) | 51 | $7,930 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,702 | $178 |
| New patient visit (60+ min) | 33 | $4,844 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $4,116 | $64 |
| Return visit (30+ min) | 43 | $3,625 | $81 |
| New patient visit (60+ min) | 20 | $3,331 | $167 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,834 | $122 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,804 | $113 |
| Return visit (30+ min) | 13 | $1,194 | $70 |
2013: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $11,029 | $90 |
| Long return visit (40+ min) | 34 | $5,242 | $125 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,074 | $175 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,801 | $62 |
| New patient visit (60+ min) | 12 | $2,155 | $180 |
| Return visit (30+ min) | 19 | $1,789 | $94 |
Medicaid work
$8,952 in 2024
Medicaid paid $8,952 for 169 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 120 | $4,929 |
| Clinic visit/encounter, all-inclusive | 26 | $4,024 |
| Return visit (30+ min) | 23 | $0 |
| 2024 | 169 | 3 | 17 | $8,952 |
| 2023 | 111 | 2 | 16 | $5,977 |
| 2021 | 64 | 2 | 12 | $3,481 |
| 2020 | 132 | 2 | 19 | $5,648 |
| 2019 | 56 | 2 | 13 | $3,074 |
| 2018 | 82 | 1 | 16 | $4,847 |
See the largest Medicaid services in earlier years
2023
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 97 | $5,070 |
| Long return visit (40+ min) | 14 | $907 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 52 | $2,631 |
| Long return visit (40+ min) | 12 | $849 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 92 | $3,840 |
| Long return visit (40+ min) | 40 | $1,808 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 44 | $2,238 |
| Long return visit (40+ min) | 12 | $836 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 82 | $4,847 |
Drugs they prescribed that Part D paid
$959,374
Pharmacies billed $959,374 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
785 generic and fewer than 11 brand-name prescriptions · $959,374 in drug cost · 79 antibiotic prescriptions to 18 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Epclusa | 15 | $358,789 | $23,919 |
| Xifaxan | 57 | $180,236 | $3,162 |
| Vemlidy | 81 | $140,467 | $1,734 |
| Ocaliva | 13 | $114,316 | $8,794 |
| Posaconazole | 13 | $34,575 | $2,660 |
See all 21 drugs
| Epclusa | 15 | $358,789 | $23,919 |
| Xifaxan | 57 | $180,236 | $3,162 |
| Vemlidy | 81 | $140,467 | $1,734 |
| Ocaliva | 13 | $114,316 | $8,794 |
| Posaconazole | 13 | $34,575 | $2,660 |
| Entecavir | 39 | $17,825 | $457 |
| Tacrolimus | 112 | $11,069 | $99 |
| Ursodiol | 58 | $8,981 | $155 |
| Mycophenolate Mofetil | 41 | $5,387 | $131 |
| Azathioprine | 77 | $4,825 | $63 |
| Lactulose | 32 | $1,556 | $49 |
| Trientine | 11 | $849 | $77 |
| Cyclosporine Modified | 12 | $756 | $63 |
| Pantoprazole | 62 | $610 | $10 |
| Tenofovir Disoproxil | 15 | $572 | $38 |
| Prednisone | 75 | $392 | $5 |
| Mycophenolic Acid | 12 | $313 | $26 |
| Constulose | 11 | $258 | $23 |
| Spironolactone | 25 | $182 | $7 |
| Furosemide | 45 | $145 | $3 |
| Carvedilol | 17 | $84 | $5 |
Year by year
| 2024 | 1,006 | 134 | None | None | $959,374 |
| 2023 | 914 | 129 | None | None | $884,589 |
| 2022 | 731 | 123 | None | None | $682,894 |
| 2021 | 925 | 118 | 2% (17) | None | $529,292 |
| 2020 | 1,054 | 133 | 2% (21) | None | $627,281 |
| 2019 | 1,044 | 134 | 2% (20) | None | $821,801 |
| 2018 | 980 | 126 | None | None | $718,498 |
| 2017 | 952 | 122 | 2% (18) | None | $2,036,379 |
| 2016 | 1,155 | 124 | 3% (32) | None | $2,519,897 |
| 2015 | 975 | 143 | 2% (21) | None | $5,127,382 |
| 2014 | 720 | 84 | 4% (28) | None | $2,138,125 |
| 2013 | 119 | 26 | None | None | $61,936 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Xifaxan | 83 | $279,908 | $3,372 |
| Vemlidy | 98 | $162,685 | $1,660 |
| Posaconazole | 12 | $55,958 | $4,663 |
| Entecavir | 24 | $15,242 | $635 |
| Tacrolimus | 91 | $10,575 | $116 |
| Trientine | 11 | $7,320 | $665 |
| Ursodiol | 47 | $7,258 | $154 |
| Azathioprine | 61 | $5,162 | $85 |
| Lactulose | 42 | $4,832 | $115 |
| Mycophenolate Mofetil | 34 | $4,291 | $126 |
| Nadolol | 19 | $1,273 | $67 |
| Mycophenolic Acid | 11 | $1,271 | $116 |
| Valganciclovir | 12 | $1,241 | $103 |
| Prednisone | 79 | $695 | $9 |
| Spironolactone | 39 | $647 | $17 |
| Pantoprazole | 24 | $541 | $23 |
| Furosemide | 43 | $397 | $9 |
2022: 15 drugs
| Xifaxan | 85 | $270,023 | $3,177 |
| Vemlidy | 84 | $119,038 | $1,417 |
| Entecavir | 25 | $12,573 | $503 |
| Tacrolimus | 49 | $7,549 | $154 |
| Azathioprine | 52 | $5,713 | $110 |
| Lactulose | 33 | $3,545 | $107 |
| Mycophenolate Mofetil | 38 | $3,492 | $92 |
| Ursodiol | 17 | $2,862 | $168 |
| Nadolol | 19 | $1,568 | $83 |
| Prednisone | 71 | $567 | $8 |
| Pantoprazole | 33 | $532 | $16 |
| Spironolactone | 27 | $513 | $19 |
| Ondansetron | 11 | $148 | $13 |
| Ciprofloxacin | 11 | $106 | $10 |
| Furosemide | 18 | $85 | $5 |
2021: 21 drugs
| Xifaxan | 78 | $219,436 | $2,813 |
| Vemlidy | 77 | $99,276 | $1,289 |
| Tacrolimus | 55 | $7,644 | $139 |
| Entecavir | 37 | $6,669 | $180 |
| Azathioprine | 65 | $5,636 | $87 |
| Budesonide Ec | 13 | $4,772 | $367 |
| Ursodiol | 23 | $3,340 | $145 |
| Sulfamethoxazole-Trimethoprim | 19 | $2,879 | $152 |
| Mycophenolate Mofetil | 32 | $2,681 | $84 |
| Lactulose | 42 | $2,503 | $60 |
| Nadolol | 18 | $1,152 | $64 |
| Pantoprazole | 47 | $830 | $18 |
| Spironolactone | 55 | $793 | $14 |
| Prednisone | 63 | $463 | $7 |
| Omeprazole | 15 | $346 | $23 |
| Furosemide | 39 | $333 | $9 |
| Ondansetron | 23 | $306 | $13 |
| Hydroxyzine | 12 | $158 | $13 |
| Hydrocodone-Acetaminophen | 13 | $109 | $8 |
| Metoprolol | 17 | $107 | $6 |
| Ciprofloxacin | 17 | $94 | $6 |
2020: 23 drugs
| Xifaxan | 84 | $233,471 | $2,779 |
| Vemlidy | 58 | $80,334 | $1,385 |
| Veltassa | 16 | $26,371 | $1,648 |
| Valganciclovir | 20 | $12,651 | $633 |
| Tacrolimus | 67 | $12,361 | $184 |
| Ursodiol | 57 | $11,076 | $194 |
| Entecavir | 36 | $6,222 | $173 |
| Lactulose | 44 | $3,826 | $87 |
| Azathioprine | 76 | $3,652 | $48 |
| Mycophenolate Mofetil | 32 | $2,411 | $75 |
| Fluconazole | 20 | $1,516 | $76 |
| Spironolactone | 54 | $1,036 | $19 |
| Nadolol | 14 | $1,031 | $74 |
| Pantoprazole | 62 | $723 | $12 |
| Prednisone | 71 | $557 | $8 |
| Furosemide | 54 | $391 | $7 |
| Ondansetron | 25 | $291 | $12 |
| Amiloride | 11 | $284 | $26 |
| Hydroxyzine | 11 | $199 | $18 |
| Ciprofloxacin | 17 | $130 | $8 |
| Hydrocodone-Acetaminophen | 13 | $59 | $5 |
| Metoprolol | 15 | $51 | $3 |
| Sulfamethoxazole-Trimethoprim | 27 | $49 | $2 |
2019: 26 drugs
| Xifaxan | 80 | $190,818 | $2,385 |
| Vemlidy | 38 | $42,769 | $1,125 |
| Valganciclovir | 16 | $26,730 | $1,671 |
| Ursodiol | 58 | $20,330 | $351 |
| Veltassa | 13 | $18,833 | $1,449 |
| Tenofovir Disoproxil | 44 | $5,545 | $126 |
| Tacrolimus | 54 | $4,047 | $75 |
| Entecavir | 25 | $2,863 | $115 |
| Lactulose | 48 | $2,736 | $57 |
| Azathioprine | 49 | $2,474 | $50 |
| Mycophenolate Mofetil | 28 | $2,288 | $82 |
| Spironolactone | 55 | $1,576 | $29 |
| Fluconazole | 26 | $987 | $38 |
| Prednisone | 65 | $566 | $9 |
| Furosemide | 56 | $463 | $8 |
| Pantoprazole | 41 | $418 | $10 |
| Ciprofloxacin | 23 | $187 | $8 |
| Fludrocortisone Acetate | 11 | $178 | $16 |
| Hydroxyzine | 13 | $165 | $13 |
| Ondansetron | 20 | $156 | $8 |
| Trazodone | 14 | $151 | $11 |
| Omeprazole | 13 | $119 | $9 |
| Sulfamethoxazole-Trimethoprim | 23 | $111 | $5 |
| Metronidazole | 11 | $73 | $7 |
| Hydrocodone-Acetaminophen | 14 | $65 | $5 |
| Metoprolol | 14 | $56 | $4 |
2018: 24 drugs
| Xifaxan | 83 | $217,063 | $2,615 |
| Mavyret | 15 | $199,626 | $13,308 |
| Vemlidy | 49 | $60,933 | $1,244 |
| Valganciclovir | 21 | $33,204 | $1,581 |
| Viread | 24 | $25,319 | $1,055 |
| Ursodiol | 33 | $16,496 | $500 |
| Tenofovir Disoproxil | 34 | $16,074 | $473 |
| Entecavir | 31 | $9,463 | $305 |
| Tacrolimus | 70 | $5,045 | $72 |
| Mycophenolate Mofetil | 23 | $3,119 | $136 |
| Azathioprine | 56 | $2,687 | $48 |
| Lactulose | 32 | $1,438 | $45 |
| Spironolactone | 70 | $1,174 | $17 |
| Fluconazole | 20 | $758 | $38 |
| Generlac | 18 | $707 | $39 |
| Constulose | 13 | $479 | $37 |
| Pantoprazole | 53 | $409 | $8 |
| Furosemide | 65 | $343 | $5 |
| Prednisone | 43 | $294 | $7 |
| Levothyroxine | 12 | $181 | $15 |
| Omeprazole | 16 | $107 | $7 |
| Ciprofloxacin | 12 | $95 | $8 |
| Sulfamethoxazole-Trimethoprim | 21 | $65 | $3 |
| Amlodipine Besylate | 14 | $61 | $4 |
2017: 25 drugs
| Harvoni | 20 | $649,321 | $32,466 |
| Zepatier | 24 | $448,703 | $18,696 |
| Xifaxan | 108 | $223,022 | $2,065 |
| Viread | 80 | $86,510 | $1,081 |
| Valganciclovir | 13 | $32,080 | $2,468 |
| Entecavir | 46 | $27,340 | $594 |
| Vemlidy | 16 | $16,081 | $1,005 |
| Ursodiol | 21 | $7,859 | $374 |
| Tacrolimus | 28 | $3,884 | $139 |
| Mycophenolate Mofetil | 27 | $2,642 | $98 |
| Azathioprine | 56 | $2,284 | $41 |
| Ribavirin | 13 | $2,156 | $166 |
| Lactulose | 32 | $1,238 | $39 |
| Amiloride | 17 | $1,223 | $72 |
| Spironolactone | 70 | $908 | $13 |
| Prednisone | 40 | $484 | $12 |
| Pantoprazole | 42 | $272 | $6 |
| Furosemide | 73 | $240 | $3 |
| Hydroxyzine | 15 | $165 | $11 |
| Omeprazole | 21 | $144 | $7 |
| Metronidazole | 11 | $144 | $13 |
| Ciprofloxacin | 14 | $87 | $6 |
| Metoprolol | 15 | $69 | $5 |
| Hydrocodone-Acetaminophen | 11 | $64 | $6 |
| Sulfamethoxazole-Trimethoprim | 15 | $49 | $3 |
2016: 26 drugs
| Harvoni | 47 | $1,473,371 | $31,348 |
| Sovaldi | 14 | $394,748 | $28,196 |
| Xifaxan | 85 | $158,790 | $1,868 |
| Viread | 95 | $82,045 | $864 |
| Valganciclovir | 30 | $71,362 | $2,379 |
| Entecavir | 55 | $38,948 | $708 |
| Ursodiol | 23 | $9,712 | $422 |
| Budesonide Ec | 14 | $5,419 | $387 |
| Tacrolimus | 29 | $1,765 | $61 |
| Azathioprine | 71 | $1,637 | $23 |
| Nystatin | 19 | $1,500 | $79 |
| Lactulose | 34 | $1,388 | $41 |
| Nadolol | 12 | $1,274 | $106 |
| Mycophenolate Mofetil | 20 | $1,168 | $58 |
| Pantoprazole | 64 | $731 | $11 |
| Spironolactone | 71 | $707 | $10 |
| Prednisone | 41 | $402 | $10 |
| Propranolol | 28 | $391 | $14 |
| Furosemide | 73 | $277 | $4 |
| Omeprazole | 27 | $237 | $9 |
| Sulfamethoxazole-Trimethoprim | 51 | $197 | $4 |
| Metronidazole | 17 | $140 | $8 |
| Hydrocodone-Acetaminophen | 16 | $138 | $9 |
| Warfarin | 14 | $134 | $10 |
| Ciprofloxacin | 17 | $111 | $7 |
| Metoprolol | 16 | $93 | $6 |
2015: 22 drugs
| Harvoni | 122 | $3,766,754 | $30,875 |
| Sovaldi | 24 | $670,080 | $27,920 |
| Olysio | 12 | $265,980 | $22,165 |
| Xifaxan | 62 | $101,659 | $1,640 |
| Viread | 38 | $34,209 | $900 |
| Entecavir | 21 | $14,205 | $676 |
| Ribavirin | 27 | $6,133 | $227 |
| Ursodiol | 16 | $6,059 | $379 |
| Tacrolimus | 26 | $2,113 | $81 |
| Nadolol | 17 | $1,755 | $103 |
| Lactulose | 29 | $1,261 | $43 |
| Spironolactone | 81 | $995 | $12 |
| Azathioprine | 34 | $921 | $27 |
| Pantoprazole | 32 | $455 | $14 |
| Prednisone | 30 | $447 | $15 |
| Furosemide | 83 | $444 | $5 |
| Omeprazole | 45 | $364 | $8 |
| Hydroxyzine | 14 | $186 | $13 |
| Levothyroxine | 14 | $165 | $12 |
| Ondansetron | 13 | $155 | $12 |
| Olanzapine | 13 | $102 | $8 |
| Sulfamethoxazole-Trimethoprim | 14 | $55 | $4 |
2014: 24 drugs
| Sovaldi | 40 | $1,145,436 | $28,636 |
| Olysio | 21 | $472,231 | $22,487 |
| Valcyte | 23 | $87,630 | $3,810 |
| Xifaxan | 36 | $49,211 | $1,367 |
| Budesonide Ec | 13 | $12,251 | $942 |
| Viread | 12 | $9,788 | $816 |
| Ribavirin | 28 | $5,906 | $211 |
| Pantoprazole | 64 | $1,056 | $17 |
| Lactulose | 30 | $1,054 | $35 |
| Cholestyramine | 12 | $1,027 | $86 |
| Spironolactone | 31 | $461 | $15 |
| Azathioprine | 23 | $372 | $16 |
| Omeprazole | 35 | $307 | $9 |
| Prednisone | 13 | $263 | $20 |
| Warfarin | 12 | $230 | $19 |
| Furosemide | 43 | $175 | $4 |
| Amlodipine Besylate | 17 | $153 | $9 |
| Metoprolol | 16 | $153 | $10 |
| Metronidazole | 11 | $99 | $9 |
| Sulfamethoxazole-Trimethoprim | 23 | $98 | $4 |
| Hydroxyzine | 15 | $95 | $6 |
| Propranolol | 15 | $92 | $6 |
| Tramadol | 14 | $92 | $7 |
| Ciprofloxacin | 11 | $57 | $5 |
2013: 1 drug
| Spironolactone | 11 | $153 | $14 |
Money from drug and device companies
$112 in 2025
| 2025 | 1 | 1 | None | $112 |
| 2024 | 3 | 3 | $2,713 | $2,760 |
| 2022 | 1 | 1 | None | $125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Cook Medical | Echotip Insight | $112 | 1 payment
|
See the published payment
| Cook Medical | Meals · 2025-07-17 | Echotip Insight | $112 |
See earlier years (2024, 2022)
2024: $2,760
| Novo Nordisk | None | $2,713 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $25 | 1 payment
|
| Albireo Pharma | Iqirvo | $23 | 1 payment
|
2022: $125
| Abbvie | Mavyret | $125 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 Peg-Fgf21 in Adults With Nonalcoholic Steatohepatitis Nash and Compensated Liver Cirrhosis · 2019 | Their institution | $46,098 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Compensated Liver Cirrhosis · 2020 | Their institution | $36,847 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis · 2020 | Their institution | $30,847 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 Peg-Fgf21 in Adults With Nonalcoholic Steatohepatitis Nash and Stage 3 Liver Fibrosis · 2019 | Their institution | $20,817 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Stage 3 Liver Fibrosis · 2021 | Their institution | $7,484 |
| Gilead Sciences, Inc. · A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Gs-0976 in Subjects With Nonalcoholic Steatohepatitis · 2019 | Their institution | $5,053 |
| E.R. Squibb & Sons, L.L.C. · A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Bms-986036 (Peg-Fgf21) in Adults With Nonalcoholic Steatohepatitis (Nash) and Compensated Liver Cirrhosis · 2021 | Their institution | $1,870 |
| E.R. Squibb & Sons, L.L.C. · Phase Iib Study - F4 48 Wk · 2020 | Their institution | $26 |
| E.R. Squibb & Sons, L.L.C. · Phase Iib Study - F4 48 Wk · 2019 | Their institution | $23 |
Professional record
- NPI
- 1891816369
- Licence
- CA 883185
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RT0003X (207RT0003X); Internal medicine (207R00000X); Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2007-04-03
- NPI last updated
- 2020-11-16
- NPI record certified
- 2020-11-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1501 Trousdale Dr Ste 215, Burlingame, CA, 94010 · 1601 Esplanade Ste 3, Chico, CA, 95926 · 4050 Dublin Blvd, Dublin, CA, 94568 · 2367 Harrison Ave, Eureka, CA, 95501 · 1189 E Herndon Ave, Fresno, CA, 93720 · 1401 Spanos Ct Ste 125, Modesto, CA, 95355 · 165 Rowland Way Ste 201, Novato, CA, 94945 · 3300 Webster St Ste 202, Oakland, CA, 94609 · 1315 Alhambra Blvd Ste 210, Sacramento, CA, 95816 · 1431 Noriega St, San Francisco, CA, 94122 · 2340 Clay St, San Francisco, CA, 94115 · 34 Mark West Springs Rd Fl 2, Santa Rosa, CA, 95403